` BCYC (Bicycle Therapeutics PLC) vs S&P 500 Comparison - Alpha Spread

BCYC
vs
S&P 500

Over the past 12 months, BCYC has underperformed S&P 500, delivering a return of -64% compared to the S&P 500's +13% growth.

Stocks Performance
BCYC vs S&P 500

Loading
BCYC
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
BCYC vs S&P 500

Loading
BCYC
S&P 500
Difference
www.alphaspread.com

Performance By Year
BCYC vs S&P 500

Loading
BCYC
S&P 500
Add Stock

Competitors Performance
Bicycle Therapeutics PLC vs Peers

S&P 500
BCYC
ABBV
AMGN
GILD
VRTX
Add Stock

Bicycle Therapeutics PLC
Glance View

Market Cap
592.4m USD
Industry
Biotechnology

Bicycle Therapeutics PLC, a pioneering force in biotechnology, was founded on a unique vision to transform medicine using a novel class of therapeutics known as Bicycles®. These are synthetic short peptides that combine the pharmacological capabilities of biologics with the manufacturing and distribution advantages of small molecules. The company's scientific ingenuity, originating from Cambridge, UK, has enabled it to engineer and develop a pipeline of drugs targeting areas with significant unmet medical needs, primarily in oncology and other severe diseases. Bicycle leverages its distinctive platform technology to design therapeutic candidates that offer high specificity and affinity, focusing on targets that have traditionally been challenging for conventional biologics and small molecules. Monetizing this innovative biotechnology hinges on Bicycle's strategic partnerships and collaborations with major pharmaceutical firms. These alliances allow the company to amplify its reach while sharing the risks and costs associated with drug development. By licensing their Bicycle® technology and therapeutic candidates to larger entities, Bicycle benefits from milestone payments and royalty streams, creating a sustainable revenue model. The company's revenue stream is thus a blend of upfront payments for access to their platform technology and the potential downstream success of these partners in developing and commercializing new therapeutic agents. Their unique approach and strong collaboration network position Bicycle Therapeutics at the forefront of next-generation drug discovery, striving to reshape treatment paradigms across multiple therapeutic areas.

BCYC Intrinsic Value
7.79 USD
Overvaluation 9%
Intrinsic Value
Price
Back to Top